Journal
CLINICAL RHEUMATOLOGY
Volume 26, Issue 6, Pages 950-952Publisher
SPRINGER LONDON LTD
DOI: 10.1007/s10067-006-0392-1
Keywords
ankylosing spondylitis; etanercept; hepatitis B; infliximab
Categories
Ask authors/readers for more resources
Anti-TNF alpha therapy for rheumatic diseases appears to be safe in patients with chronic hepatitis C. However, the administration of anti-TNF alpha agents without initiation of prophylactic antiviral therapy (lamivudine 100 mg/day) in patients with chronic HBV infection results in exacerbation of liver disease. In this report, we describe our experience of long-term anti-TNF alpha therapy for ankylosing spondylitis in two inactive HBsAg carriers without preemptive antiviral treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available